Abstract:Background Primary ovarian insufficiency (POI) refers to the loss of ovarian function before the age of 40 years and results in amenorrhea and infertility. POI has diverse causes, but a common cause is exposure to gonadotoxic chemotherapy for cancer treatment. Due to the risk of developing POI, patients who want to preserve their fertility may consider various procedures for fertility preservation. However, current fertility preservation options are highly invasive, carry substantial risks, and have uncertain success rates. Recent studies from our group and others reported that mesenchymal stem cells (MSCs) and MSC-derived exosomes can restore ovarian functions in preclinical models of POI by restoring damaged cells and inhibiting apoptosis. Although the restorative effect of MSC-derived exosomes has been well reported in previous studies, the potential of MSC-derived exosomes for preventing ovarian damage has not been fully elucidated. Objective We hypothesized that the antiapoptotic potential of MSC-derived exosomes may protect ovarian tissue from chemotherapy-induced damage. Study design In this study, we delivered MSC-derived exosomes directly into mouse ovaries before chemotherapy. Sixty mice were divided into three groups (20 per group), which were labeled the control, CTx (chemotherapy), and FP (fertility protection) groups. Only the FP group mice received exosomes, while the control and CTx group mice received saline. After exosome injection, the CTx and FP groups of mice were subjected to chemotherapy treatment to induce ovarian damage. After chemotherapy, we evaluated the protective effects of exosome treatment on ovarian function, such as estrus cyclicity, serum hormone levels, and the fertility rate, by comparing these outcomes between the CTx and FP groups. These outcomes were also compared with those of the control group for comparison with outcomes under healthy conditions. Results After intraovarian injection of exosomes before chemotherapy, the mice were able to maintain their estrus cycle (4–5-day cyclicity), serum AMH level (66.06±26.40 ng/ml, not significantly different from that of the healthy controls), folliculogenesis (32.2±11.3 in the CTx group/46.4±14.1 in the FP group, p<0.05), steroidogenesis marker StAR gene expression (0.44±0.11-fold in the CTx group and 0.88±0.31-fold in the FP group, p<0.05), and fertility (2 of 8 in the CTx group and 5 of 8 in the FP group), preventing chemotherapy-induced damage. We found that exosome treatment before chemotherapy can preserve ovarian function and protect fertility through the overexpression of ABC transporters, such as ABCB1b (10.17±17.75-fold in the CTx group and 44.14±33.25-fold in the FP group; p<0.05), and ABCC10 (3.25±0.59-fold in the CTx group and 5.36±1.86-fold in the FP group; p<0.05). Conclusion In this study, we present a novel fertility protection method using MSC-derived exosomes. We conclude that MSC-derived exosomes are a promising simple treatment option for fertility protection in reproductive-age patients receiving gonadotoxic chemotherapy.

Menstrual blood-derived endometrial stem cell, a unique and promising alternative in the stem cell-based therapy for chemotherapy-induced premature ovarian insufficiency

Menstrual blood-derived endometrial stem cells ameliorate the viability of ovarian granulosa cells injured by cisplatin through activating autophagy.

Endometrial Stem Cells Repair Injured Endometrium and Induce Angiogenesis Via AKT and ERK Pathways.

Human Endometrial Mesenchymal Stem Cells Restore Ovarian Function Through Improving the Renewal of Germline Stem Cells in a Mouse Model of Premature Ovarian Failure

The Multi-Functional Roles of Menstrual Blood-Derived Stem Cells in Regenerative Medicine

Menstrual Blood Stem Cells-Derived Exosomes as Promising Therapeutic Tools in Premature Ovarian Insufficiency Induced by Gonadotoxic Systemic Anticancer Treatment

Menstrual Blood-Derived Stem Cells: Toward Therapeutic Mechanisms, Novel Strategies, and Future Perspectives in the Treatment of Diseases

Extracellular Vesicles from Ipsc-Mscs Alleviate Chemotherapy-Induced Mouse Ovarian Damage Via the ILK-PI3K/AKT Pathway

Application of mesenchymal stem cell therapy for premature ovarian insufficiency: Recent advances from mechanisms to therapeutics

Enhanced Homing of Mesenchymal Stem Cells for in Situ Niche Remodeling and Bone Regeneration

Menstrual Blood-Derived Endometrial Stem Cells Ameliorate Ovarian Senescence by Relieving Oxidative Stress-Induced Inflammation

The potent paracrine effect of umbilical cord mesenchymal stem cells mediates mitochondrial quality control to restore chemotherapy-induced damage in ovarian granulosa cells

Research progress on the mechanism of mesenchymal stem cells therapy for premature ovarian failure

Fertility protection: A novel approach using pretreatment with mesenchymal stem cell exosomes to prevent chemotherapy-induced ovarian damage in mouse model.

Mesenchymal stem cells therapy improves ovarian function in premature ovarian failure: a systematic review and meta-analysis based on preclinical studies

Human Umbilical Cord Mesenchymal Stem Cells Improve Ovarian Function in Chemotherapy-Induced Premature Ovarian Failure Mice Through Inhibiting Apoptosis and Inflammation via a Paracrine Mechanism

The remodeling of ovarian function: targeted delivery strategies for mesenchymal stem cells and their derived extracellular vesicles

Premature ovarian insufficiency: pathogenesis and therapeutic potential of mesenchymal stem cell

Human umbilical cord mesenchymal stem cells alleviate chemotherapy-induced premature ovarian insufficiency mouse model by suppressing ferritinophagy-mediated ferroptosis in granulosa cells

Human Mesenchymal Stem Cells Partially Reverse Infertility in Chemotherapy-Induced Ovarian Failure

Human embryonic stem cell-derived mesenchymal stem cells improved premature ovarian failure